179 related articles for article (PubMed ID: 16735446)
1. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.
Luciani JJ; Depetris D; Usson Y; Metzler-Guillemain C; Mignon-Ravix C; Mitchell MJ; Megarbane A; Sarda P; Sirma H; Moncla A; Feunteun J; Mattei MG
J Cell Sci; 2006 Jun; 119(Pt 12):2518-31. PubMed ID: 16735446
[TBL] [Abstract][Full Text] [Related]
2. Subcellular distribution of HP1 proteins is altered in ICF syndrome.
Luciani JJ; Depetris D; Missirian C; Mignon-Ravix C; Metzler-Guillemain C; Megarbane A; Moncla A; Mattei MG
Eur J Hum Genet; 2005 Jan; 13(1):41-51. PubMed ID: 15470359
[TBL] [Abstract][Full Text] [Related]
3. Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX.
Ishov AM; Vladimirova OV; Maul GG
J Cell Sci; 2004 Aug; 117(Pt 17):3807-20. PubMed ID: 15252119
[TBL] [Abstract][Full Text] [Related]
4. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1.
Dellaire G; Eskiw CH; Dehghani H; Ching RW; Bazett-Jones DP
J Cell Sci; 2006 Mar; 119(Pt 6):1034-42. PubMed ID: 16492707
[TBL] [Abstract][Full Text] [Related]
5. Viruses as hijackers of PML nuclear bodies.
Möller A; Schmitz ML
Arch Immunol Ther Exp (Warsz); 2003; 51(5):295-300. PubMed ID: 14626429
[TBL] [Abstract][Full Text] [Related]
6. KAP1 depletion increases PML nuclear body number in concert with ultrastructural changes in chromatin.
Kepkay R; Attwood KM; Ziv Y; Shiloh Y; Dellaire G
Cell Cycle; 2011 Jan; 10(2):308-22. PubMed ID: 21228624
[TBL] [Abstract][Full Text] [Related]
7. [Research advances on function of promyelocytic leukemia (PML) protein].
He PC; Zhang M; Wang F
Ai Zheng; 2003 Dec; 22(12):1359-62. PubMed ID: 14693070
[TBL] [Abstract][Full Text] [Related]
8. Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells.
Rivera OJ; Song CS; Centonze VE; Lechleiter JD; Chatterjee B; Roy AK
Mol Endocrinol; 2003 Jan; 17(1):128-40. PubMed ID: 12511612
[TBL] [Abstract][Full Text] [Related]
9. PML nuclear bodies and apoptosis.
Takahashi Y; Lallemand-Breitenbach V; Zhu J; de Thé H
Oncogene; 2004 Apr; 23(16):2819-24. PubMed ID: 15077145
[TBL] [Abstract][Full Text] [Related]
10. PML nuclear bodies as sites of epigenetic regulation.
Torok D; Ching RW; Bazett-Jones DP
Front Biosci (Landmark Ed); 2009 Jan; 14(4):1325-36. PubMed ID: 19273133
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies.
Block GJ; Eskiw CH; Dellaire G; Bazett-Jones DP
Mol Cell Biol; 2006 Dec; 26(23):8814-25. PubMed ID: 16966371
[TBL] [Abstract][Full Text] [Related]
12. Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 Tax oncoprotein.
Ariumi Y; Ego T; Kaida A; Matsumoto M; Pandolfi PP; Shimotohno K
Oncogene; 2003 Mar; 22(11):1611-9. PubMed ID: 12642864
[TBL] [Abstract][Full Text] [Related]
13. PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein.
Daniels MJ; Marson A; Venkitaraman AR
Nat Struct Mol Biol; 2004 Nov; 11(11):1114-21. PubMed ID: 15467728
[TBL] [Abstract][Full Text] [Related]
14. PML tumor suppressor protein is required for HCV production.
Kuroki M; Ariumi Y; Hijikata M; Ikeda M; Dansako H; Wakita T; Shimotohno K; Kato N
Biochem Biophys Res Commun; 2013 Jan; 430(2):592-7. PubMed ID: 23219818
[TBL] [Abstract][Full Text] [Related]
15. Patient mutations alter ATRX targeting to PML nuclear bodies.
Bérubé NG; Healy J; Medina CF; Wu S; Hodgson T; Jagla M; Picketts DJ
Eur J Hum Genet; 2008 Feb; 16(2):192-201. PubMed ID: 17957225
[TBL] [Abstract][Full Text] [Related]
16. Body language: the function of PML nuclear bodies in apoptosis regulation.
Hofmann TG; Will H
Cell Death Differ; 2003 Dec; 10(12):1290-9. PubMed ID: 12934066
[TBL] [Abstract][Full Text] [Related]
17. CK2 and PML: regulating the regulator.
Lallemand-Breitenbach V; de Thé H
Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of histone H3.3 deposition in proliferating and senescent cells reveals a DAXX-dependent targeting to PML-NBs important for pericentromeric heterochromatin organization.
Corpet A; Olbrich T; Gwerder M; Fink D; Stucki M
Cell Cycle; 2014; 13(2):249-67. PubMed ID: 24200965
[TBL] [Abstract][Full Text] [Related]
19. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
20. PML bodies: a meeting place for genomic loci?
Ching RW; Dellaire G; Eskiw CH; Bazett-Jones DP
J Cell Sci; 2005 Mar; 118(Pt 5):847-54. PubMed ID: 15731002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
